Prognostic significance of Memorial Sloan-Kettering prognostic score in small-cell lung cancer patients.

To assess the potential factors with predictive value for survival in small-cell lung cancer (SCLC) patients and to develop a nomogram prediction model. We retrospectively screened and analyzed patients with pathologically confirmed SCLC from April 2015 to December 2021. A total of 167 patients with SCLC were included. According to the Memorial Sloan-Kettering prognostic score (MPS), patients were divided into three groups: group 0 (n = 65), group 1 (n = 69) and group 2 (n = 33). The multivariate analysis showed that MPS was an independent prognostic factor for progression-free and overall survival in SCLC patients (p < 0.05). The nomogram showed that MPS was the most influential factor for overall survival. MPS is an independent prognostic factor for overall and progression-free survival in SCLC patients and performed better than other indicators used in this study.